Skip to main content
Top
Published in: Journal of Neuro-Oncology 3/2007

01-12-2007 | Clinical-Patient Studies

Pentavalent technetium-99m dimercaptosuccinic acid [99mTc-(V)DMSA] brain scintitomography—a plausible non-invasive depicter of glioblastoma proliferation and therapy response

Authors: Spyridon Tsiouris, Ioannis Pirmettis, Theodoros Chatzipanagiotou, Nikolaos Ptohis, Vassilios Papantoniou

Published in: Journal of Neuro-Oncology | Issue 3/2007

Login to get access

Abstract

The biological behavior and prognosis of gliomas depend largely on cellular proliferation, resistance to chemotherapy, and metastatic potential. Proliferative propensity has significant implications on patient management but its assessment requires tissue sampling; the non-invasive estimation of brain tumor proliferation represents therefore a major goal. Pentavalent technetium-99 m dimercapto-succinic acid [99mTc-(V)DMSA] is a tumor-seeking radiotracer displaying affinity for gliomas; its intracellular accumulation is directly linked to cell proliferation. We performed a tomographic 99mTc-(V)DMSA brain scan in a 35-year-old male baring a recurrent glioblastoma multiforme, to depict its proliferative disposition. The patient had been diagnosed 14 months earlier and had been submitted to surgery, followed by adjuvant radiotherapy and temozolomide-based chemotherapy. On clinical suspicion of recurrence 5 months later, magnetic resonance imaging (MRI) revealed a lesion at the site of preceded surgery, which was treated by imatinib mesylate. No improvement was ascertained the following months and radiographic assessment verified tumor progression. Scintitomography revealed avid radiotracer uptake in the entirety of the lesion (the distribution of radioactivity closely conforming to the morphological tumor boundaries), an indication that the neoplasm demonstrated no substantial proliferation decline in response to imatinib. The patient deceased a few weeks later. Mounting in vivo and in vitro evidence indicates that 99mTc-(V)DMSA is a credible non-invasive proliferation depicter, its cellular accumulation linked closely to phosphate uptake and kinase pathway activation. A potential role in patient management, prognosis estimation, and therapy response monitoring could occur for this tracer.
Literature
1.
go back to reference Mankoff DA, Shields AF, Krohn KA (2005) PET imaging of cellular proliferation. Radiol Clin North Am 43:153–167PubMedCrossRef Mankoff DA, Shields AF, Krohn KA (2005) PET imaging of cellular proliferation. Radiol Clin North Am 43:153–167PubMedCrossRef
2.
go back to reference Chen W, Cloughesy T, Kamdar N et al (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46:945–952PubMed Chen W, Cloughesy T, Kamdar N et al (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46:945–952PubMed
3.
go back to reference Papantoniou VJ, Souvatzoglou MA, Valotassiou VJ et al (2004) Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer. Breast Cancer Res 6:R56–R62 (available from URL: http://breast-cancer-research.com/content/6/2/R56, cited 11 Dec 2003) Papantoniou VJ, Souvatzoglou MA, Valotassiou VJ et al (2004) Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer. Breast Cancer Res 6:R56–R62 (available from URL: http://​breast-cancer-research.​com/​content/​6/​2/​R56, cited 11 Dec 2003)
4.
go back to reference Denoyer D, Perek N, Le Jeune N et al (2005) Correlation between 99mTc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines. Eur J Nucl Med Mol Imaging 32:820–827PubMedCrossRef Denoyer D, Perek N, Le Jeune N et al (2005) Correlation between 99mTc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines. Eur J Nucl Med Mol Imaging 32:820–827PubMedCrossRef
5.
go back to reference Papantoniou V, Tsiouris S (2005) In vitro verification of the correlation of in vivo 99mTc-(V)DMSA uptake with cellular proliferation rate. Eur J Nucl Med Mol Imaging 32:1240–1241PubMedCrossRef Papantoniou V, Tsiouris S (2005) In vitro verification of the correlation of in vivo 99mTc-(V)DMSA uptake with cellular proliferation rate. Eur J Nucl Med Mol Imaging 32:1240–1241PubMedCrossRef
6.
go back to reference Guillermet S, Vuillez JP, Fontaine E et al (2006) Cellular uptake of 99mTcN-NOET in human leukaemic HL-60 cells is related to calcium channel activation and cell proliferation. Eur J Nucl Med Mol Imaging 33:66–72PubMedCrossRef Guillermet S, Vuillez JP, Fontaine E et al (2006) Cellular uptake of 99mTcN-NOET in human leukaemic HL-60 cells is related to calcium channel activation and cell proliferation. Eur J Nucl Med Mol Imaging 33:66–72PubMedCrossRef
7.
go back to reference Papantoniou V, Christodoulidou J, Papadaki E et al (2001) 99mTc-(V)DMSA scintimammography in the assessment of breast lesions. Comparative study with 99mTc-MIBI. Eur J Nucl Med 28:923–928PubMedCrossRef Papantoniou V, Christodoulidou J, Papadaki E et al (2001) 99mTc-(V)DMSA scintimammography in the assessment of breast lesions. Comparative study with 99mTc-MIBI. Eur J Nucl Med 28:923–928PubMedCrossRef
8.
go back to reference Hirano T, Otake H, Shibasaki T et al (1997) Differentiating histologic malignancy of primary brain tumours: pentavalent technetium-99m-DMSA. J Nucl Med 38:20–26PubMed Hirano T, Otake H, Shibasaki T et al (1997) Differentiating histologic malignancy of primary brain tumours: pentavalent technetium-99m-DMSA. J Nucl Med 38:20–26PubMed
9.
go back to reference Hirano T, Otake H, Kazama K et al (1997) Technetium-99m (V)-DMSA and thallium-201 in brain tumour imaging: correlation with histology and malignant grade. J Nucl Med 38:1741–1749PubMed Hirano T, Otake H, Kazama K et al (1997) Technetium-99m (V)-DMSA and thallium-201 in brain tumour imaging: correlation with histology and malignant grade. J Nucl Med 38:1741–1749PubMed
10.
go back to reference Papantoniou V, Tsiouris S, Mainta E et al (2005) Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography. Breast Cancer Res 7:R33–R45 (available from URL: http://breast-cancer-research.com/content/7/1/R33, cited 8 Nov 2004) Papantoniou V, Tsiouris S, Mainta E et al (2005) Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammography. Breast Cancer Res 7:R33–R45 (available from URL: http://​breast-cancer-research.​com/​content/​7/​1/​R33, cited 8 Nov 2004)
11.
go back to reference Papantoniou V, Tsiouris S, Koutsikos J et al (2006) Scintimammographic detection of usual ductal breast hyperplasia with increased proliferation rate at risk for malignancy. Nucl Med Commun 27:911–917PubMedCrossRef Papantoniou V, Tsiouris S, Koutsikos J et al (2006) Scintimammographic detection of usual ductal breast hyperplasia with increased proliferation rate at risk for malignancy. Nucl Med Commun 27:911–917PubMedCrossRef
12.
go back to reference Le Jeune N, Dubois F, Bin V et al (2006) Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer 99mTc-(v)-DMSA. Eur J Cancer 42:1004–1013PubMedCrossRef Le Jeune N, Dubois F, Bin V et al (2006) Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer 99mTc-(v)-DMSA. Eur J Cancer 42:1004–1013PubMedCrossRef
13.
go back to reference Kilic T, Alberta JA, Zdunek PR et al (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60:5143–5150PubMed Kilic T, Alberta JA, Zdunek PR et al (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60:5143–5150PubMed
14.
go back to reference Buchdunger E, Cioffi CL, Law N et al (2002) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139–145 Buchdunger E, Cioffi CL, Law N et al (2002) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139–145
15.
go back to reference Servidei T, Riccardi A, Sanguinetti M et al (2006) Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol 208:220–228PubMedCrossRef Servidei T, Riccardi A, Sanguinetti M et al (2006) Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J Cell Physiol 208:220–228PubMedCrossRef
16.
go back to reference Denoyer D, Perek N, Le Jeune N et al (2004) Evidence that 99mTc-(V)-DMSA uptake is mediated by NaPi cotransporter type III in tumour cell lines. Eur J Nucl Med Mol Imaging 31:77–84PubMedCrossRef Denoyer D, Perek N, Le Jeune N et al (2004) Evidence that 99mTc-(V)-DMSA uptake is mediated by NaPi cotransporter type III in tumour cell lines. Eur J Nucl Med Mol Imaging 31:77–84PubMedCrossRef
17.
go back to reference Plate KH, Breier G, Farrell CL et al (1992) Platelet-derived growth factor receptor-beta is induced during tumour development and upregulated during tumour progression in endothelial cells in human gliomas. Lab Invest 67:529–534PubMed Plate KH, Breier G, Farrell CL et al (1992) Platelet-derived growth factor receptor-beta is induced during tumour development and upregulated during tumour progression in endothelial cells in human gliomas. Lab Invest 67:529–534PubMed
18.
go back to reference Fleming TP, Saxena A, Clark WC et al (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550–4553PubMed Fleming TP, Saxena A, Clark WC et al (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550–4553PubMed
19.
go back to reference Uhrbom L, Hesselager G, Nister M et al (1998) Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58:5275–5279PubMed Uhrbom L, Hesselager G, Nister M et al (1998) Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58:5275–5279PubMed
20.
go back to reference Dai C, Celestino JC, Okada Y et al (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913–1925PubMedCrossRef Dai C, Celestino JC, Okada Y et al (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913–1925PubMedCrossRef
21.
go back to reference Lokker NA, Sullivan CM, Hollenbach SJ et al (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729–3735PubMed Lokker NA, Sullivan CM, Hollenbach SJ et al (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729–3735PubMed
22.
go back to reference Shih AH, Dai C, Hu X et al (2004) Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64:4783–4789PubMedCrossRef Shih AH, Dai C, Hu X et al (2004) Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64:4783–4789PubMedCrossRef
23.
go back to reference Rankin S, Rozengurt E (1994) Platelet-derived growth factor modulation of focal adhesion kinase (p125FAK) and paxillin tyrosine phosphorylation in Swiss 3T3 cells. Bell-shaped dose response and cross-talk with bombesin. J Biol Chem 269:704–710PubMed Rankin S, Rozengurt E (1994) Platelet-derived growth factor modulation of focal adhesion kinase (p125FAK) and paxillin tyrosine phosphorylation in Swiss 3T3 cells. Bell-shaped dose response and cross-talk with bombesin. J Biol Chem 269:704–710PubMed
24.
go back to reference Kakita A, Suzuki A, Nishiwaki K et al (2004) Stimulation of Na-dependent phosphate transport by platelet-derived growth factor in rat aortic smooth muscle cells. Atherosclerosis 174:17–24PubMedCrossRef Kakita A, Suzuki A, Nishiwaki K et al (2004) Stimulation of Na-dependent phosphate transport by platelet-derived growth factor in rat aortic smooth muscle cells. Atherosclerosis 174:17–24PubMedCrossRef
25.
go back to reference Haberler C, Gelpi E, Marosi C et al (2006) Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol 76:105–109PubMedCrossRef Haberler C, Gelpi E, Marosi C et al (2006) Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol 76:105–109PubMedCrossRef
26.
go back to reference Muzi M, Spence AM, O’Sullivan F et al (2006) Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med 47:1612–1621PubMed Muzi M, Spence AM, O’Sullivan F et al (2006) Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med 47:1612–1621PubMed
27.
go back to reference Le Jeune FP, Dubois F, Blond S et al (2006) Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. J Neurooncol 77:177–183PubMedCrossRef Le Jeune FP, Dubois F, Blond S et al (2006) Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. J Neurooncol 77:177–183PubMedCrossRef
28.
go back to reference Alexiou GA, Fotopoulos AD, Papadopoulos A et al (2007) Evaluation of brain tumor recurrence by 99mTc-Tetrofosmin SPECT: A prospective pilot study. Ann Nucl Med; doi: 10.1007/s12149-007-0027-x Alexiou GA, Fotopoulos AD, Papadopoulos A et al (2007) Evaluation of brain tumor recurrence by 99mTc-Tetrofosmin SPECT: A prospective pilot study. Ann Nucl Med; doi: 10.1007/s12149-007-0027-x
29.
go back to reference Minutoli F, Angileri FF, Cosentino S et al (2003) 99mTc-MIBI SPECT in distinguishing neoplastic from nonneoplastic intracerebral hematoma. J Nucl Med 44:1566–1573PubMed Minutoli F, Angileri FF, Cosentino S et al (2003) 99mTc-MIBI SPECT in distinguishing neoplastic from nonneoplastic intracerebral hematoma. J Nucl Med 44:1566–1573PubMed
30.
go back to reference Alexiou GA, Bokharhii JA, Kyritsis AP et al (2006) Tc-99m Tetrofosmin SPECT for the differentiation of a cerebellar hemorrhage mimicking a brain metastasis from a renal cell carcinoma. J Neurooncol 78:207–208PubMedCrossRef Alexiou GA, Bokharhii JA, Kyritsis AP et al (2006) Tc-99m Tetrofosmin SPECT for the differentiation of a cerebellar hemorrhage mimicking a brain metastasis from a renal cell carcinoma. J Neurooncol 78:207–208PubMedCrossRef
Metadata
Title
Pentavalent technetium-99m dimercaptosuccinic acid [99mTc-(V)DMSA] brain scintitomography—a plausible non-invasive depicter of glioblastoma proliferation and therapy response
Authors
Spyridon Tsiouris
Ioannis Pirmettis
Theodoros Chatzipanagiotou
Nikolaos Ptohis
Vassilios Papantoniou
Publication date
01-12-2007
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2007
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-007-9410-7

Other articles of this Issue 3/2007

Journal of Neuro-Oncology 3/2007 Go to the issue